Table 1 PROTECT Trial, post-hoc analysis of ITTIV population
ITTIV population N = 299 (includes all patients from USA, Canada/Australia) | Low dose oral-heparin (60,000 IU/1.5 g SNAC) 30 days) | High dose oral-heparin (90,000 IU/2.25 g SNAC) 30 days | Injectable LOVENOX ® 30 mg s.c b.i.d.)10-day followed by placebo (to day 30) |
|---|---|---|---|
Total DVT rate | 27% | 18% | 28% |
Relative Risk Reduction | 4% | 55% | Â |